Professor Ciechanover is notably a Nobel Prize laureate, having won the 2004 Nobel Prize in Chemistry. He will lend his expertise to OncoHost as it continues its mission of combining life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy.
"We are delighted to have Professor Ciechanover, an eminent researcher and physician, join our team. His profound scientific knowledge in protein biology and fundamental discoveries in protein turnover that awarded him the 2004 Nobel Prize in Chemistry will be an invaluable contribution to our research efforts in identifying effective personalized cancer treatments," said Dr. Ofer Sharon, CEO of OncoHost. "OncoHost's unique approach to host response analysis and our methods to overcome therapy resistance will be further improved by Prof. Ciechanover's vast experience and innovative ideas in the field of biochemistry."
The Nobel Prize is not all Ciechanover has won. He is a thoroughly decorated researcher, having also been awarded the 2000 Albert Lasker Prize for Basic Medical Research, the 2003 Israel Prize for Biological Research, and having been named to the Israeli National Academy of Sciences and Humanities, the European Molecular Biology Organization, among other reputable academies.
"I look forward to implementing my research and knowledge on tumor biology and various disease progression mechanisms to work with OncoHost in understanding host response related processes," said Professor Ciechanover. "Proteomic analysis is allowing us to make great advances in personalized cancer care. With OncoHost's host response profiling platform, the future of personalized cancer care is no longer a distant reality, but within our grasp."